• 1
    Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis 2001; 12: 32737.
  • 2
    Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27: 8190.
  • 3
    Pivalizza EG, Abramson DC, King FS Jr, Thromboelastography with heparinase in orthotopic liver transplantation. J Cardiothorac Vasc Anesth 1998; 12: 3058.
  • 4
    Royston D, Von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth 2001; 86: 5758.
  • 5
    Van Deventer SJ, Buller HR, Ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 25206.
  • 6
    Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 116572.
  • 7
    Hollenstein U, Homoncik M, Knobl P, Pernerstorfer T, Graggaber J, Eichler HG, Handler S, Jilma B. Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans. Clin Pharmacol Ther 2002; 71: 36874.
  • 8
    Jilma B, Marsik C, Mayr F, Graninger MT, Taylor FB Jr, Ribel MC, Erhardtsen E, Handler S, Eichler HG. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 2002; 72: 40310.
  • 9
    Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B. Recombinant human activated protein C [rhAPC; drotrecogin alfa (activated)] has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003; 102: 20938.
  • 10
    Aras O, Shet A, Bach RR, Hysjulien JL, Slungaard A, Hebbel RP, Escolar G, Jilma B, Key NS. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004; 103: 454553.
  • 11
    Ungerstedt JS, Soop A, Sollevi A, Blomback M. Bedside monitoring of coagulation activation after challenging healthy volunteers with intravenous endotoxin. Thromb Res 2003; 111: 32934.
  • 12
    Marsik C, Quehenberger P, Mackman N, Osterud B, Luther T, Jilma B. Validation of a novel tissue factor assay in experimental human endotoxemia. Thromb Res 2003; 111: 3115.
  • 13
    De Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, Van Deventer SJ, Van Der Poll T. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 11249.
  • 14
    Van Der Poll T, Levi M, Buller HR, Van Deventer SJ, De Boer JP, Hack CE, Ten Cate JW. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174: 72932.
  • 15
    Pernerstorfer T, Hollenstein U, Hansen JB, Stohlawetz P, Eichler HG, Handler S, Speiser W, Jilma B. Lepirudin blunts endotoxin-induced coagulation activation. Blood 2000; 95: 172934.
  • 16
    Reiter R, Derhaschnig U, Spiel A, Keen P, Cardona F, Mayr F, Jilma B. Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost 2003; 90: 898903.
  • 17
    Derhaschnig U, Pachinger C, Schweeger-Exeli I, Marsik C, Jilma B. Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia. Thromb Haemost 2003; 90: 105460.
  • 18
    Fries D, Innerhofer P, Klingler A, Berresheim U, Mittermayr M, Calatzis A, Schobersberger W. The effect of the combined administration of colloids and lactated Ringer's solution on the coagulation system: an in vitro study using thrombelastograph coagulation analysis (ROTEG). Anesth Analg 2002; 94: 12807.
  • 19
    Camenzind V, Bombeli T, Seifert B, Jamnicki M, Popovic D, Pasch T, Spahn DR. Citrate storage affects Thrombelastograph analysis. Anesthesiology 2000; 92: 12429.
  • 20
    Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 5518.
  • 21
    Vig S, Chitolie A, Bevan DH, Halliday A, Dormandy J. Thromboelastography: a reliable test? Blood Coagul Fibrinolysis 2001; 12: 55561.
  • 22
    Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 15263.
  • 23
    Bock M, De Haan J, Beck KH, Gutensohn K, Hertfelder HJ, Karger R, Heim MU, Beeser H, Weber D, Kretschmer V. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol 1999; 106: 898904.
  • 24
    Khurana S, Mattson JC, Westley S, O'Neill WW, Timmis GC, Safian RD. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 1997; 130: 40111.
  • 25
    Bowbrick VA, Mikhailidis DP, Stansby G. Influence of platelet count and activity on thromboelastography parameters. Platelets 2003; 14: 21924.
  • 26
    Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, Jilma B. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000; 111: 12502.
  • 27
    Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br J Haematol 1999; 106: 77783.
  • 28
    Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, Savidge GF, Pasi J, Machin SJ. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999; 10: 2531.
  • 29
    Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3: 203943.
  • 30
    Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW Jr, Starzl TE, Winter PM. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 88896.
  • 31
    Gillies BS. Thromboelastography and liver transplantation. Semin Thromb Hemost 1995; 21(Suppl. 4): 459.
  • 32
    Viana JS, Pereira MG, Lozano L, Vieira H, Palmeiro A, Lourenco M, Tavares CA, Seco C, Neves S, Bento C, Perdigoto R, Ferrer-Antunes C, Craveiro AL, Furtado L. Thrombelastographic evidence of hyperfibrinolysis during liver transplantation for familial amyloidotic polyneuropathy ATTR met 30. Transplant Proc 2000; 32: 26456.
  • 33
    Kaku R, Matsumi M, Ichiyama M, Kajihara H, Fujii H, Ohashi I, Mizobuchi S, Morita K. [Massive bleeding due to hyperfibrinolysis during living-related liver transplantation for terminal liver cirrhosis; report of two cases]. Masui 2003; 52: 11959.
  • 34
    Kang Y. Transfusion based on clinical coagulation monitoring does reduce hemorrhage during liver transplantation. Liver Transpl Surg 1997; 3: 6559.
  • 35
    Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B, Amiral J, Richter V, Wagner OF. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 1999; 159: 85763.
  • 36
    Carroll RC, Craft RM, Chavez JJ, Snider CC, Bresee SJ, Cohen E. A Thrombelastograph whole blood assay for clinical monitoring of NSAID-insensitive transcellular platelet activation by arachidonic acid. J Lab Clin Med 2005; 146: 305.
  • 37
    Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 2005; 145: 30915.